ArticleBMC infectious diseases2025
Clinical features and treatment outcomes of Mycobacterium colombiense pulmonary disease: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A rare case report: The impact ofFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMycobacterium colombiense (M. col), a rare member of the Mycobacterium avium complex (MAC), primarily infects immunocompromised individuals and often causes disseminated disease with high mortality. Clinical understanding of its manifestations and outcomes remains limited.
methodsWe conducted a retrospective study at a single tertiary center in Sichuan, China, reviewing records of patients diagnosed with nontuberculous mycobacterial pulmonary disease (NTM-PD) from 2009 to 2024. Data collected included demographics, clinical symptoms, imaging findings, laboratory results, treatment regimens, and outcomes. Comparative analyses were performed between patients with M. col pulmonary infection and those with other MAC pulmonary infections.
resultsAmong 299 NTM-PD cases, 134 (44.8%) were diagnosed with MAC pulmonary infection, including 11 (3.7%) confirmed as M. col pulmonary infection. Compared to other MAC infections, patients with M. col exhibited higher rates of disseminated disease (36.4% vs. 7.3%, p < 0.05), fever (45.5%), dyspnea (72.7%), and concurrent infections (72.7% vs. 37.4%, p < 0.05), along with elevated eosinophil counts and lower hemoglobin levels. Imaging findings and antibiotic susceptibility showed no significant differences compared to other MAC infections. Treatment outcomes were comparable between the two groups when guideline-based regimens were followed.
conclusionM. col demonstrates a predilection for extrapulmonary dissemination and polymicrobial infections, exhibiting distinct clinical and laboratory features compared to other MAC subspecies, but responds similarly to standard MAC antibiotic therapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.